Veeda Lifesciences: Comprehensive Company Profile

Background

Overview

Veeda Lifesciences, established in 2004 and formerly known as Veeda Clinical Research, is a global Contract Research Organization (CRO) headquartered in Ahmedabad, India. The company offers a comprehensive suite of services encompassing preclinical research, early and late-phase clinical trials (Phase I-IV), bioequivalence studies, and biopharmaceutical services. Veeda Lifesciences operates across multiple regions, including India, Europe, and North America, providing end-to-end drug development solutions to support the advancement of innovative, biosimilar, and generic drugs.

Mission and Vision

Mission: To be a global CRO with execution capabilities across diverse geographies through a borderless approach. As an agile organization, Veeda Lifesciences brings speed and efficiency in identifying and implementing science-based, technology-led, client-specific solutions, while ensuring the highest standards of quality in everything they do.

Vision: To become the premier global development partner for the advancement of bio-therapeutics and small molecules through science and technology, leveraging AI and real-world data.

Industry Significance

Veeda Lifesciences holds a significant position in the CRO industry, recognized for its scientific excellence, regulatory compliance, and ethical practices. The company's integrated service model spans the entire drug development lifecycle, offering expertise in preclinical studies, bioavailability/bioequivalence studies, early and late-phase clinical trials, bioanalytical services, and biopharmaceutical solutions. This comprehensive approach enables Veeda Lifesciences to support biotech and pharmaceutical companies in developing innovative therapies and generic drugs for patients worldwide.

Key Strategic Focus

Core Objectives

Integrated Service Delivery: Veeda Lifesciences aims to provide end-to-end CRO solutions under one roof, tailoring services to meet the evolving needs of clients and adapting as projects progress.

Technological Advancement: The company leverages advanced technology, including AI and real-world data, to optimize processes and outcomes, delivering precise solutions that accelerate research for partners.

Global Expansion: With a presence in nine countries and sites across 26 geographies, Veeda Lifesciences seeks to offer global reach and local expertise, ensuring equitable access to trials and improved health outcomes for patients worldwide.

Areas of Specialization

Preclinical Research: Through its subsidiary Bioneeds, Veeda Lifesciences offers preclinical research services, including method development, validation, and throughput sample analysis, delivering precise insights that empower confident decisions and streamline regulatory filings.

Clinical Trials: The company conducts Phase I-IV trials for drugs and biotherapeutics, providing comprehensive support across various therapeutic domains, including oncology, ophthalmology, and dermatology.

Bioanalytical Services: Veeda Lifesciences provides method development and sample analysis for studies, ensuring accurate, efficient analysis that enables well-informed decisions for successful biotherapeutic development programs.

Key Technologies Utilized

AI and Real-World Data: The company integrates AI-driven analytics and real-world data to eliminate operational redundancies and expedite clinical study workflows, enhancing the efficiency and effectiveness of drug development processes.

Primary Markets Targeted

Biopharmaceutical Companies: Veeda Lifesciences partners with innovator and generic companies, utilizing its high-quality infrastructure and global network of clinical trial sites to launch novel therapies and new products for patients worldwide.

Financials and Funding

Funding History

Veeda Lifesciences has successfully raised a total of $83.32 million across eight funding rounds. The most recent funding activity was a Series B round of $28.91 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities.

Notable Investors

The company has secured backing from 35 investors, including institutional, venture fund, and angel investors. Prominent investors include Actis, Acorn Capital, and Systematix. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

Utilization of Capital

The capital raised is intended to support Veeda Lifesciences' strategic expansion, product development, market penetration, and operational scaling, driving long-term value creation and competitive advantage.

Pipeline Development

As a Contract Research Organization, Veeda Lifesciences does not develop its own pharmaceutical products but provides comprehensive services to support the development of its clients' pipelines. The company's expertise spans the entire drug development lifecycle, from preclinical research to late-phase clinical trials, bioanalytical services, and biopharmaceutical solutions. Veeda Lifesciences has a strong foundation in global oncology studies and offers solutions across multiple therapeutic domains, accelerating pipelines through AI and advanced real-world data capabilities.

Technological Platform and Innovation

Proprietary Technologies

AI-Driven Analytics: Veeda Lifesciences leverages AI to transform documents into actionable analytics, streamlining study management and enhancing decision-making processes.

Integrated Systems: The company integrates Clinical Trial Management Systems (CTMS) and trial builder software to reduce trial setup times and speed up study progress from initiation to closeout.